Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pyloriinfection when combined with rabeprazole, amoxicillin and clarithromycin
AIM: The mucoprotective agents, sofalcone and polaprezinc have anti-Helicobacter pylori ( H pylorl) activities. We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole, amoxicillin and clarithromycin for Helicobacter pylori infection. METHODS: One hundred an...
Saved in:
| Published in: | World journal of gastroenterology : WJG Vol. 11; no. 11; pp. 1629 - 1633 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
Shunkaikai Inoue Hospital,Takaramachi 8-9, Nagasaki, Japan%Second Department of Internal Medicine, Nagasaki University School of Medicine, Sakamoto 1-7-1, Nagasaki, Japan%Department of Molecular Pathology, Atomic Bomb Disease Institute, Nagasaki University School of Medicine,Sakamoto 12-4, Nagasaki, Japan
2005
Department of Digestive Disease, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, Jiangsu Province, China%Shunkaikai Inoue Hospital,Takaramachi 8-9, Nagasaki, Japan Second Department of Internal Medicine, Nagasaki University School of Medicine, Sakamoto 1-7-1, Nagasaki, Japan |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | AIM: The mucoprotective agents, sofalcone and polaprezinc have anti-Helicobacter pylori ( H pylorl) activities. We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole, amoxicillin and clarithromycin for Helicobacter pylori infection. METHODS: One hundred and sixty-five consecutive outpatients with peptic ulcer and Hpyloriinfection were randomly assigned to one of the following three groups and medicated for 7 d. Group A: triple therapy with rabeprazole (10 mg twice daily), clarithromycin (200 mg twice daily) and amoxicillin (750 mg twice daily). Group B: sofalcone (100 mg thrice daily) plus the triple therapy. Group C: polaprezinc (150 mg twice daily) plus the triple therapy. Eradication was considered successful if ^13C-urea breath test was negative at least 4 wk after cessation of eradication regimens or successive famotidine in the cases of active peptic ulcer. RESULTS: On intention-to-treat basis, Hpyloricure was achieved in 43 of 55 (78.2%) patients, 47 of 54 (87.0%) and 45 of 56 (80.4%) for the groups A, B and C respectively. Using per protocol analysis, the eradication rates were 81.1% (43/53), 94.0% (47/50) and 84.9% (45/53) respectively. There was a significant difference in the cure rates between group A and B. Adverse events occurred in 10, 12 and 11 patients, from groups A, B and C respectively, but the events were generally mild. CONCLUSION: The addition of sofalcone, but not polaprezinc, significantly increased the cure rate of Hpylori infection when combined with the rabeprazole-amoxicillinclarithromycin regimen. |
|---|---|
| Bibliography: | R515 R978.1 14-1219/R |
| ISSN: | 1007-9327 2219-2840 |